Dynamic responses of cancer-associated fibroblasts to therapy in primary liver cancer
Cancer Letters · 2026-08 · 653 · 218566
DOI: 10.1016/j.canlet.2026.218566 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026-08. Verfasst von Qi Ruan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute, Faculty of Health, Medicine and Behavioural Science, The University of Queensland, Brisbane, QLD, 4102, Australia; Gallipoli Medica…. Hauptthemen laut MEDLINE: Liver Neoplasms, Cancer-Associated Fibroblasts, Carcinoma, Hepatocellular, Cholangiocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gallipoli Medical Research Foundation.
Abstract (Originalsprache)
Cancer-associated fibroblasts (CAFs) are central players in the tumour microenvironment (TME) of primary liver cancer, influencing both cancer progression and treatment response. Studies involving single-cell RNA sequencing and spatial multi-omics have significantly expanded our understanding of CAF heterogeneity and functional diversity, although consolidated markers to identify CAF subtypes and therapy-dependent plasticity remain largely unknown. In this review, CAF subpopulations, including their markers and functions, are comprehensively summarised in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The spatial distribution of CAF subtypes from tumour core to boundary correlates with their phenotypes and functions. We focus on mapping dynamic changes of CAF subtypes in response to therapy, including chemotherapy and immunotherapy, and how these changes influence treatment response and prognosis in liver cancer. Finally, we discuss key challenges in targeting specific CAF subtypes and general CAF activation pathways in current clinical trials. This review provides a holistic view of the current and future landscape of CAF-targeting and CAF-regulating strategies in combination with standard-of-care treatments for liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Frazer Institute, Faculty of Health, Medicine and Behavioural Science, The University of Queensland, Brisbane, QLD, 4102, Australia; Gallipoli Medical Research, Greenslopes Private Hospital, Brisbane, QLD, 4120, Austral…
- Frazer Institute, Faculty of Health, Medicine and Behavioural Science, The University of Queensland, Brisbane, QLD, 4102, Australia; Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisba…
- Princess Alexandra Hospital, Queensland Health, Brisbane, QLD, 4102, Australia.
- Gallipoli Medical Research, Greenslopes Private Hospital, Brisbane, QLD, 4120, Australia; Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Queensland, Australia.
Förderung
- Gallipoli Medical Research Foundation
Zitieren
APA
Ruan, Q., Tan, Y. R., Kim, M., Li, D., Bridle, K., O'Rourke, T., Crawford, D., & Liang, X. (2026). Dynamic responses of cancer-associated fibroblasts to therapy in primary liver cancer. Cancer Letters, 653, 218566. https://doi.org/10.1016/j.canlet.2026.218566
Vancouver
Ruan Q, Tan YR, Kim M, Li D, Bridle K, O'Rourke T, et al. Dynamic responses of cancer-associated fibroblasts to therapy in primary liver cancer. Cancer Letters. 2026;653:218566. doi:10.1016/j.canlet.2026.218566
BibTeX
@article{Ruan2026,
author = {Ruan, Qi and Tan, Ying Rong and Kim, Minwoo and Li, Damon and Bridle, Kim and O'Rourke, Thomas and Crawford, Darrell and Liang, Xiaowen},
title = {Dynamic responses of cancer-associated fibroblasts to therapy in primary liver cancer},
journal = {Cancer Letters},
year = {2026},
volume = {653},
pages = {218566},
doi = {10.1016/j.canlet.2026.218566}
}
EUVIMED